Tolerability and antitumor activity of paclitaxel is improved by the addition of nilotinib in patients with refractory solid tumors Coyne, G., Kummar, S., Zlott, J., Juwara, L., Takebe, N., Hogu, M., Anderson, L., Collins, J., Piekarz, R., Streicher, H., Sharon, E., Mittra, A., Khan, S., Miller, B., Navas, T., Srivastava, A., Parchment, R., Rubinstein, L., Doroshow, J. H., Chen, A. P. AMER ASSOC CANCER RESEARCH. 2019

View details for DOI 10.1158/1535-7163.TARG-19-C008

View details for Web of Science ID 000510047200255